Encouraging patients to participate in AML trials

Despite recent approvals of drugs targeting acute myeloid leukemia (AML), overall survival and complete remission rates remain suboptimal. In this interview, Eytan Stein, MD, from the Memorial Sloan K... Author: VJHemOnc Added: 05/29/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts